Testing a new medication for kidney dialysis patients with overactive parathyroid

Plain-English translation of NCT07122401 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can better control overactive parathyroid glands in people who receive regular kidney dialysis. About 424 people will be randomly assigned to receive either or (a current standard treatment) for 26 weeks. The study will measure blood levels and bone health to compare how well the medication works and how safe it is.

People on long-term kidney dialysis often develop overactive parathyroid glands, which causes their calcium and phosphorus levels to become dangerously unbalanced. Current treatments like help, but researchers want to see if this new medication can work even better with fewer side effects.

Do you qualify?

You likely qualify if…

you are at least 18 years old and have a body mass index between 18 and 35
you have been receiving regular kidney dialysis three times a week for at least 12 weeks
you have been diagnosed with secondary hyperparathyroidism with parathyroid hormone levels of at least 400 pg/mL
you have adequate calcium levels in your blood as measured by your doctor
you are able to understand the study information and willing to give informed consent

You likely don't qualify if…

you have had parathyroid surgery, ablation, or radiation within the past 6 months
you have had stomach bleeding or ulcers within the past 6 months
you have serious heart failure or dangerous heart rhythm problems
you are currently taking cinacalcet or similar medications within the past 2 weeks
you have severe uncontrolled high blood pressure or have had seizures within the past year

What participation looks like

If you join this study, you'll be randomly assigned to receive either the new medication or the standard treatment for 26 weeks. One group gets the new medication through an IV injection plus a dummy oral pill, while the other group gets the existing treatment as an oral pill plus a dummy IV injection (this keeps the study fair and unbiased). During the 26 weeks, your doctor will regularly check your blood levels, calcium, phosphorus, and bone health to see how well the treatment is working.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Zhongshan Hospital, Shanghai, Shanghai Municipality